27391263|t|Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study
27391263|a|Molecular characterization of cancer samples is hampered by tumor tissue availability in metastatic castration-resistant prostate cancer (mCRPC) patients. We reported the results of prospective PETRUS study of biomarker assessment in paired primary prostatic tumors, metastatic biopsies and circulating tumor cells (CTCs). Among 54 mCRPC patients enrolled, 38 (70%) had biopsies containing more than 50% tumour cells. 28 (52%) patients were analyzed for both tissue samples and CTCs. FISH for AR - amplification and TMPRSS2 - ERG translocation were successful in 54% and 32% in metastatic biopsies and primary tumors, respectively. By comparing CellSearch and filtration (ISET)-enrichment combined to four color immunofluorescent staining, we showed that CellSearch and ISET isolated distinct subpopulations of CTCs: CTCs undergoing epithelial-to-mesenchymal transition, CTC clusters and large CTCs with cytomorphological characteristics but no detectable markers were isolated using ISET. Epithelial CTCs detected by the CellSearch were mostly lost during the ISET-filtration. AR - amplification was detected in CellSearch -captured CTCs, but not in ISET -enriched CTCs which harbor exclusively AR gain of copies. Eighty-eight percent concordance for ERG-rearrangement was observed between metastatic biopsies and CTCs even if additional ERG-alteration patterns were detected in ISET -enriched CTCs indicating a higher heterogeneity in CTCs. Molecular screening of metastatic biopsies is achievable in a multicenter context. Our data indicate that CTCs detected by the CellSearch and the ISET-filtration systems are not only phenotypically but also genetically different. Close attention must be paid to CTC characterization since neither approach tested here fully reflects the tremendous phenotypic and genetic heterogeneity present in CTCs from mCRPC patients.
27391263	0	10	Phenotypic	T033	UMLS:C1852220
27391263	40	52	tumor tissue	T017	UMLS:C0475358
27391263	57	80	circulating tumor cells	T017	UMLS:C0027625
27391263	98	145	metastatic castration-resistant prostate cancer	T038	UMLS:C1328504
27391263	149	155	report	T170	UMLS:C0684224
27391263	165	189	PETRUS prospective study	T062	UMLS:C0033522
27391263	190	234	Molecular characterization of cancer samples	T170	UMLS:C1513386
27391263	250	262	tumor tissue	T017	UMLS:C0475358
27391263	279	326	metastatic castration-resistant prostate cancer	T038	UMLS:C1328504
27391263	328	333	mCRPC	T038	UMLS:C1328504
27391263	348	356	reported	T058	UMLS:C0700287
27391263	372	396	prospective PETRUS study	T062	UMLS:C0033522
27391263	400	420	biomarker assessment	T062	UMLS:C1879847
27391263	439	455	prostatic tumors	T038	UMLS:C0376358
27391263	457	467	metastatic	T038	UMLS:C0027627
27391263	468	476	biopsies	T058	UMLS:C0005558
27391263	481	504	circulating tumor cells	T017	UMLS:C0027625
27391263	506	510	CTCs	T017	UMLS:C0027625
27391263	522	527	mCRPC	T038	UMLS:C1328504
27391263	560	568	biopsies	T058	UMLS:C0005558
27391263	594	606	tumour cells	T017	UMLS:C0431085
27391263	631	639	analyzed	T062	UMLS:C0936012
27391263	649	663	tissue samples	T017	UMLS:C0475358
27391263	668	672	CTCs	T017	UMLS:C0027625
27391263	674	678	FISH	T062	UMLS:C0162789
27391263	683	685	AR	T017	UMLS:C1367578
27391263	688	701	amplification	T062	UMLS:C1517480
27391263	706	713	TMPRSS2	T017	UMLS:C1336641
27391263	716	719	ERG	T017	UMLS:C0599295
27391263	720	733	translocation	T038	UMLS:C1315049
27391263	768	778	metastatic	T038	UMLS:C0027627
27391263	779	787	biopsies	T058	UMLS:C0005558
27391263	792	806	primary tumors	T038	UMLS:C0677930
27391263	835	845	CellSearch	T058	UMLS:C0200925
27391263	850	866	filtration (ISET	T058	UMLS:C0200925
27391263	902	928	immunofluorescent staining	T058	UMLS:C1318793
27391263	945	955	CellSearch	T058	UMLS:C0200925
27391263	960	964	ISET	T058	UMLS:C0200925
27391263	1001	1005	CTCs	T017	UMLS:C0027625
27391263	1007	1011	CTCs	T017	UMLS:C0027625
27391263	1023	1059	epithelial-to-mesenchymal transition	T038	UMLS:C1523298
27391263	1061	1073	CTC clusters	T017	UMLS:C0027625
27391263	1084	1088	CTCs	T017	UMLS:C0027625
27391263	1135	1145	detectable	T201	UMLS:C3830527
27391263	1146	1153	markers	T201	UMLS:C0005516
27391263	1174	1178	ISET	T058	UMLS:C0200925
27391263	1191	1195	CTCs	T017	UMLS:C0027625
27391263	1196	1204	detected	T033	UMLS:C0442726
27391263	1212	1222	CellSearch	T058	UMLS:C0200925
27391263	1251	1266	ISET-filtration	T058	UMLS:C0200925
27391263	1268	1270	AR	T017	UMLS:C1367578
27391263	1273	1286	amplification	T062	UMLS:C1517480
27391263	1291	1299	detected	T033	UMLS:C0442726
27391263	1303	1313	CellSearch	T058	UMLS:C0200925
27391263	1324	1328	CTCs	T017	UMLS:C0027625
27391263	1341	1345	ISET	T058	UMLS:C0200925
27391263	1356	1360	CTCs	T017	UMLS:C0027625
27391263	1386	1388	AR	T017	UMLS:C1367578
27391263	1442	1459	ERG-rearrangement	T038	UMLS:C2826127
27391263	1481	1491	metastatic	T038	UMLS:C0027627
27391263	1492	1500	biopsies	T058	UMLS:C0005558
27391263	1505	1509	CTCs	T017	UMLS:C0027625
27391263	1529	1543	ERG-alteration	T038	UMLS:C2826127
27391263	1558	1566	detected	T033	UMLS:C0442726
27391263	1570	1574	ISET	T058	UMLS:C0200925
27391263	1585	1589	CTCs	T017	UMLS:C0027625
27391263	1627	1631	CTCs	T017	UMLS:C0027625
27391263	1643	1652	screening	T058	UMLS:C1710032
27391263	1656	1666	metastatic	T038	UMLS:C0027627
27391263	1667	1675	biopsies	T058	UMLS:C0005558
27391263	1695	1714	multicenter context	T062	UMLS:C0206012
27391263	1739	1743	CTCs	T017	UMLS:C0027625
27391263	1744	1752	detected	T033	UMLS:C0442726
27391263	1760	1770	CellSearch	T058	UMLS:C0200925
27391263	1779	1802	ISET-filtration systems	T058	UMLS:C0200925
27391263	1895	1898	CTC	T017	UMLS:C0027625
27391263	1981	1991	phenotypic	T033	UMLS:C1852220
27391263	2029	2033	CTCs	T017	UMLS:C0027625
27391263	2039	2044	mCRPC	T038	UMLS:C1328504